Regenxbio Q4 Revenue Seen Rising 48.5% to $31.49M with EPS Beat Odds
Regenxbio is forecast to report a $1.01 loss per share for the quarter ended December 2025 on $31.49 million in revenue, up 48.5% year-over-year. A 115.84% Earnings ESP combined with a Zacks Rank of #3 indicates a likely upside surprise to consensus estimates.
1. Q4 Earnings Estimates
Regenxbio is expected to report a loss per share of $1.01 for the quarter ended December 2025, while generating revenues of $31.49 million, representing a 48.5% increase from the year-ago period.
2. Earnings ESP and Zacks Rank
The Most Accurate Estimate exceeds the consensus, producing an Earnings ESP of 115.84%. Combined with a Zacks Rank of #3 (Hold), this suggests a high probability of an earnings surprise above the consensus.
3. Earnings Surprise History
Over the last four quarters, Regenxbio has beaten consensus EPS estimates twice, including in the most recent quarter when it narrowed its loss to $1.02 per share versus an expected $1.08 loss.
4. Upcoming Investor Conferences
Regenxbio will present at the Leerink Partners Global Healthcare Conference on March 9, the Barclays Global Healthcare Conference on March 10, and the RBC Virtual Ophthalmology Conference on March 24, with live and archived webcasts available.